Materialise NV (NASDAQ:MTLS), a leading provider of additive
manufacturing and medical software solutions and of sophisticated
3D printing services, today announced its financial results for the
fourth quarter and full year ended December 31, 2022.
Highlights – Fourth Quarter 2022
- Total revenue increased 10% to 62,703 kEUR for the fourth
quarter of 2022 from 56,989 kEUR for the 2021 period.
- Adjusted EBITDA amounted to 4,258 kEUR for the fourth quarter
of 2022 compared to 10,490 kEUR for the 2021 period.
- Net loss for the fourth quarter of 2022 was (4,588) kEUR, or
(0.08) EUR per diluted share, compared to a profit of 4,762 kEUR,
or 0.08 EUR per diluted share, for the 2021 period.
Highlights – Full Year 2022
- Total revenue increased 13% to 232,023 kEUR for 2022 from
205,450 kEUR for 2021.
- Total deferred revenues from annual software sales and
maintenance fees increased 7,635 kEUR to 42,780 kEUR compared to
December 31, 2021.
- Adjusted EBITDA was 19,014 kEUR for 2022 compared to 32,490
kEUR for 2021.
- Net loss for 2022 was (2,153) kEUR, or (0.04) EUR per diluted
share, compared to a profit of 13,145 kEUR, or 0.23 EUR per diluted
share, for 2021.
- Total cash was 140,867 kEUR at the end of 2022.
Executive Chairman Peter Leys commented, “Amidst the
macro-economic and geo-political turbulence of 2022, Materialise
prioritized the sustainability of our top-line growth over the
maximization of short term profits. In 2022, we increased our
revenues by 13% and grew our deferred revenues by more than 20%. In
addition, we continued to strategically invest in our growth
businesses despite significant inflationary pressures on labor,
energy and materials costs and accelerated the consolidation with
both Link3D and Identify3D, as a basis for our future cloud-based
recurring income. These added costs in addition to certain one-time
items weighed on our overall profitability for the year, with
Adjusted EBITDA decreasing to 19,014 kEUR. However, with positive
cash flow from operating activities of almost 25,000 kEUR in 2022
and cash and cash equivalents in excess of 140,000 kEUR at year
end, we have the liquidity to support these investments and believe
this was the right choice for Materialise, positioning us well for
more profitable growth in the coming years.”
Fourth Quarter 2022 Results
Total revenue for the fourth quarter of 2022 increased 10.0% to
62,703 kEUR from 56,989 kEUR for the fourth quarter of 2021.
Adjusted EBITDA amounted to 4,258 kEUR, compared to 10,490 kEUR for
the same period in 2021. The Adjusted EBITDA margin (Adjusted
EBITDA divided by total revenue) for the fourth quarter of 2022 was
6.8%, compared to 18.4% for the fourth quarter of 2021.
Revenue from our Materialise Software segment decreased 4.0% to
11,699 kEUR from 12,183 kEUR for the same quarter last year.
Adjusted EBITDA for the segment amounted to (1,441) kEUR compared
to 5,518 kEUR while the Adjusted EBITDA margin for the segment was
(12.3)%, compared to 45.3% for the prior-year period.
Revenue from our Materialise Medical segment increased 17.3% to
24,254 kEUR for the fourth quarter of 2022, compared to 20,682 kEUR
for the same period in 2021. Adjusted EBITDA for the segment was
6,355 kEUR compared to 6,358 kEUR, while the Adjusted EBITDA margin
for the segment was 26.2% compared to 30.7%.
Revenue from our Materialise Manufacturing segment increased
10.9% to 26,750 kEUR from 24,124 kEUR for the fourth quarter of
2021. Adjusted EBITDA for the segment increased to 1,506 kEUR
compared 990 kEUR, while the Adjusted EBITDA margin for the segment
was 5.6%, compared to 4.1% for the prior-year period.
Gross profit increased 7.5% to 35,681 kEUR for the fourth
quarter of 2022 from 33,198 kEUR for the same period last year.
Gross profit as a percentage of revenue was 56.9%, compared to
58.3%.
Research and development (“R&D”), sales and marketing
(“S&M”) and general and administrative (“G&A”) expenses
increased, in the aggregate, 28.3% to 37,829 kEUR for the fourth
quarter of 2022 from 29,481 kEUR for the fourth quarter of
2021.
Net other operating result was 593 kEUR compared to 1,260 kEUR
for the fourth quarter of 2021.
Operating result was (1,554) kEUR, compared to 4,976 kEUR for
the fourth quarter of 2021.
Net financial result for the fourth quarter of 2022 was (3,436)
kEUR, compared to 275 kEUR for the fourth quarter of 2021, mainly
as a result of currency exchange losses.
The fourth quarter of 2022 contained net income tax income of
402 kEUR, compared to net tax expense of (490) kEUR for the fourth
quarter of 2021.
As a result of the above, net loss for the fourth quarter of
2022 was (4,588) kEUR, compared to a net profit of 4,762 kEUR for
the same period in 2021. Total comprehensive income for the fourth
quarter of 2022 was (7,623) kEUR, compared to a profit of 1,832
kEUR for the 2021 period.
Full Year 2022 Results
Total revenues for the year ended December 31, 2022 increased
12.9% to 232,023 kEUR from 205,450 kEUR for the year ended December
31, 2021. Adjusted EBITDA for 2022 amounted to 19,014 kEUR compared
to 32,490 kEUR for 2021. The Adjusted EBITDA margin was 8.2%,
compared to 15.8% in 2021.
Revenues from our Materialise Software segment increased 1.8% to
43,688 kEUR for the year ended December 31, 2022 compared to 42,902
kEUR for the year ended December 31, 2021. The segment’s Adjusted
EBITDA amounted to 1,514 kEUR compared to 15,705 kEUR. The
segment’s Adjusted EBITDA margin was 3.5% in 2022, compared to
36.6% in 2021.
Revenues from our Materialise Medical segment grew by 15.6% for
the year ended December 31, 2022 to 84,846 kEUR from 73,368 kEUR
for the year ended December 31, 2021. The segment’s Adjusted EBITDA
amounted to 18,822 kEUR compared to 20,669 kEUR. The segment’s
Adjusted EBITDA margin was 22.2% in 2022, compared to 28.2% in
2021.
Revenues from our Materialise Manufacturing segment increased
16.0% to 103,489 kEUR for the year ended December 31, 2022 from
89,180 kEUR for the year ended December 31, 2021. The segment’s
Adjusted EBITDA increased 31.1% to 8,229 kEUR from 6,275 kEUR. The
segment’s Adjusted EBITDA margin increased to 8.0% in 2022 from
7.0% for 2021.
Operating profit amounted to (2,872) kEUR for the year ended
December 31, 2022 compared to a profit of 12,217 kEUR in the prior
year.
Net financial income amounted to 1,694 kEUR, compared to net
financial income of 1,519 kEUR for the year ended December 31,
2021. Income taxes amounted to (975) kEUR compared to (591) kEUR
for the year ended December 31, 2021. Net loss was (2,153) kEUR for
2022 compared to a net profit of 13,145 kEUR in 2021.
At December 31, 2022, we had cash and equivalents of 140,867
kEUR compared to 196,028 kEUR at December 31, 2021. Gross debt
amounted to 80,980 kEUR (of which 19,960 kEUR was short term),
compared to 99,107 kEUR at December 31, 2021.
Cash flow from operating activities for the year ended December
31, 2022 was 24,709 kEUR compared to 25,845 kEUR in the year ended
December 31, 2021. Total capital expenditures for the year ended
December 31, 2022 amounted to 24,773 kEUR.
Net shareholders’ equity at December 31, 2022 was 228,928 kEUR
compared to 232,578 kEUR at December 31, 2021.
2023 Guidance
Mr. Leys concluded, “We currently expect Materialise to post
another year of double-digit revenue growth, with revenues totaling
between 255,000 and 260,000 kEUR in 2023. As in 2022, we expect our
Materialise Medical segment and our Materialise Manufacturing
segment will be the main drivers of that growth. While we expect
sales of our Materialise Software segment will also grow, this
growth may not be fully reflected in the segment’s revenues due to
the changing cloud-based subscription business model we are
introducing there.
“Assuming that inflation stabilizes in 2023, we expect our
continued revenue growth to gradually result in a stronger Adjusted
EBITDA, which we currently anticipate to total between 25,000 and
30,000 kEUR for 2023. We expect our three segments to contribute to
our Adjusted EBITDA in line with their contributions to our revenue
growth.
“At the same time, we want to note that the developments in
Ukraine will likely have an important impact on the European and
global economy as well as on the continuity of the important
services we source from our brave workforce in Kyiv and could,
therefore, also have a significant effect on our results for 2023.
We will continue to monitor these developments, which remain
unpredictable.”
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental
financial measures of its financial performance. EBITDA is
calculated as net profit(loss) plus income taxes, financial
expenses (less financial income), shares of profit or loss in a
joint venture and depreciation and amortization. Adjusted EBITDA is
determined by adding share-based compensation expenses,
acquisition-related expenses of business combinations, impairments
and revaluation of fair value due to business combinations to
EBITDA. Management believes these non-IFRS measures to be important
measures as they exclude the effects of items which primarily
reflect the impact of long-term investment and financing decisions,
rather than the performance of the company’s day-to-day operations.
As compared to net profit(loss), these measures are limited in that
they do not reflect the periodic costs of certain capitalized
tangible and intangible assets used in generating revenues in the
company’s business, or the charges associated with impairments.
Management evaluates such items through other financial measures
such as capital expenditures and cash flow provided by operating
activities. The company believes that these measurements are useful
to measure a company’s ability to grow or as a valuation
measurement. The company’s calculation of EBITDA and Adjusted
EBITDA may not be comparable to similarly titled measures reported
by other companies. EBITDA and Adjusted EBITDA should not be
considered as alternatives to net profit(loss) or any other
performance measure derived in accordance with IFRS. The company’s
presentation of EBITDA and Adjusted EBITDA should not be construed
to imply that its future results will be unaffected by unusual or
non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into
U.S. dollars at specified rates solely for the convenience of
readers. Unless otherwise noted, all translations from euros to
U.S. dollars in this document were made at a rate of EUR 1.00 to
USD 1.0666, the reference rate of the European Central Bank on
December 31, 2022.
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast
to discuss its financial results for the fourth quarter of 2022 and
other matters on Tuesday, February 14, 2023 at 8:30 a.m. ET/2:30
p.m. CET. Company participants on the call will include Wilfried
Vancraen, Founder and Chief Executive Officer; Peter Leys,
Executive Chairman; and Johan Albrecht, Chief Financial Officer. A
question-and-answer session will follow management’s remarks. To
access the call by phone, please click the link below at least 15
minutes prior to the scheduled start time and you will be provided
with dial-in details. Participants can choose to dial in or receive
a call to connect to Materialise’s conference call.
-
https://register.vevent.com/register/BI658e710186554ddfb27b37ef31c78ee1
The conference call will also be broadcast live over the
internet with an accompanying slide presentation, which can be
accessed on the company’s website at
http://investors.materialise.com. A webcast of the conference call
will be archived on the company's website for one year.
About Materialise
Materialise incorporates 30 years of 3D printing experience into
a range of software solutions and 3D printing services, which form
the backbone of the 3D printing industry. Materialise’s open and
flexible solutions enable players in a wide variety of industries,
including healthcare, automotive, aerospace, art and design, and
consumer goods, to build innovative 3D printing applications that
aim to make the world a better and healthier place. Headquartered
in Belgium, with branches worldwide, Materialise combines the
largest groups of software developers in the industry with one of
the largest and most complete 3D printing facilities in the
world.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, regarding, among other things, our intentions, beliefs,
assumptions, projections, outlook, analyses or current
expectations, plans, objectives, strategies and prospects, both
financial and business, including statements concerning, among
other things, our current estimates for fiscal 2023 revenue and
Adjusted EBITDA, results of operations, cash needs, capital
expenditures, expenses, financial condition, liquidity, prospects,
growth and strategies (including how our business, results of
operations and financial condition could be impacted by the ongoing
military conflict between Ukraine and Russia and economic sanctions
related thereto as well as by inflation and increased labor, energy
and materials costs), and the trends and competition that may
affect the markets, industry or us. Such statements are subject to
known and unknown uncertainties and risks. When used in this press
release, the words “estimate,” “expect,” “anticipate,” “project,”
“plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,”
“might,” “aim,” “should,” and variations of such words or similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon the expectations of
management under current assumptions at the time of this press
release. These expectations, beliefs and projections are expressed
in good faith and the Company believes there is a reasonable basis
for them. However, the Company cannot offer any assurance that our
expectations, beliefs and projections will actually be achieved. By
their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics
and industry change, and depend on economic circumstances that may
or may not occur in the future or may occur on longer or shorter
timelines than anticipated. We caution you that forward-looking
statements are not guarantees of future performance and involve
known and unknown risks, uncertainties and other factors that are
in some cases beyond our control. All of the forward-looking
statements are subject to risks and uncertainties that may cause
the Company's actual results to differ materially from our
expectations, including risk factors described in the Company's
most recent annual report on Form 20-F filed with the U.S.
Securities and Exchange Commission. There are a number of risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements contained in
this press release.
The Company is providing this information as of the date of this
press release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise, unless it
has obligations under the federal securities laws to update and
disclose material developments related to previously disclosed
information.
Consolidated income statements (Unaudited)
for the three months endedDecember 31, for the twelve
months endedDecember 31, In '000
2022
2022
2021
2022
2021
U.S.$ € € € € Revenue
66,879
62,703
56,989
232,023
205,450
Cost of Sales
(28,822
)
(27,022
)
(23,791
)
(103,258
)
(87,278
)
Gross Profit
38,058
35,681
33,198
128,765
118,172
Gross profit as % of revenue
56.9
%
56.9
%
58.3
%
55.5
%
57.5
%
Research and development expenses
(12,259
)
(11,494
)
(6,896
)
(37,568
)
(26,891
)
Sales and marketing expenses
(18,435
)
(17,284
)
(13,421
)
(62,125
)
(49,151
)
General and administrative expenses
(9,654
)
(9,051
)
(9,165
)
(35,140
)
(33,315
)
Net other operating income (expenses)
633
593
1,260
3,196
3,402
Operating (loss) profit
(1,657
)
(1,554
)
4,976
(2,872
)
12,217
Financial expenses
(4,497
)
(4,216
)
(919
)
(4,420
)
(4,101
)
Financial income
832
780
1,195
6,114
5,620
Share in loss of joint venture
-
-
-
-
-
(Loss) profit before taxes
(5,322
)
(4,990
)
5,252
(1,178
)
13,736
Income Taxes
429
402
(490
)
(975
)
(591
)
Net (loss) profit for the period
(4,893
)
(4,588
)
4,762
(2,153
)
13,145
Net (loss) profit attributable to:
-
The owners of the parent
(4,885
)
(4,580
)
4,769
(2,123
)
13,154
Non-controlling interest
(9
)
(8
)
(7
)
(29
)
(9
)
Earning per share attributable to owners of the
parent Basic
(0.08
)
(0.08
)
0.08
(0.04
)
0.23
Diluted
(0.08
)
(0.08
)
0.08
(0.04
)
0.23
Weighted average basic shares outstanding
59,064
59,064
58,892
59,064
56,685
Weighted average diluted shares outstanding
59,064
59,064
59,025
59,064
56,843
Consolidated statements of comprehensive income
(Unaudited)
for the three months endedDecember 31, for the twelve
months endedDecember 31, In 000€
2022
2022
2021
2022
2021
U.S.$ € € € € Net profit
(loss) for the period
(4,893
)
(4,588
)
4,762
(2,153
)
13,145
Other comprehensive income Recycling Exchange
difference on translation of foreign operations
(3,139
)
(2,943
)
561
(1,427
)
1,565
Non-recycling Fair value adjustments through OCI - Equity
instruments
(99
)
(92
)
(3,491
)
(92
)
(3,443
)
Other comprehensive income (loss), net of taxes
(3,237
)
(3,035
)
(2,930
)
(1,519
)
(1,878
)
Total comprehensive income (loss) for the year, net of taxes
(8,131
)
(7,623
)
1,832
(3,672
)
11,267
Total comprehensive income (loss) attributable to: The owners of
the parent
(8,123
)
(7,616
)
1,839
(3,643
)
11,276
Non-controlling interests
(7
)
(7
)
(7
)
(28
)
(9
)
Consolidated statement of financial position
(Unaudited)
As ofDecember 31, As ofDecember 31, In 000€
2022
2021
Assets Non-current assets Goodwill
44,155
18,726
Intangible assets
37,875
31,668
Property, plant & equipment
94,276
84,451
Right-of-Use assets
8,420
9,054
Investments in joint ventures
-
-
Deferred tax assets
1,186
227
Investments in convertible loans
3,494
3,560
Investments in non-listed equity instruments
307
399
Other non-current assets
5,135
7,519
Total non-current assets
194,847
155,604
Current assets Inventories
16,081
11,295
Trade receivables
51,043
41,541
Other current assets
8,424
8,940
Cash and cash equivalents
140,867
196,028
Total current assets
216,414
257,804
Total assets
411,262
413,408
As ofDecember 31, As ofDecember 31, In 000€
2022
2021
Equity and liabilities Equity Share capital
4,487
4,489
Share premium
233,895
233,872
Retained earnings and other reserves
(9,427
)
(5,784
)
Equity attributable to the owners of the parent
228,955
232,577
Non-controlling interest
(27
)
1
Total equity
228,928
232,578
Non-current liabilities Loans & borrowings
55,873
72,637
Lease liabilities
5,147
5,268
Deferred tax liabilities
4,312
4,371
Deferred income
9,277
4,952
Other non-current liabilities
1,611
2,167
Total non-current liabilities
76,220
89,395
Current liabilities Loans & borrowings
17,058
17,849
Lease liabilities
2,902
3,353
Trade payables
25,629
20,171
Tax payables
1,246
783
Deferred income
41,722
33,307
Other current liabilities
17,558
15,972
Total current liabilities
106,115
91,435
Total equity and liabilities
411,262
413,408
Consolidated statement of cash flows (Unaudited)
for the twelve months endedDecember 31, In 000€
2022
2021
Operating activities Net (loss) profit for the period
(2,153
)
13,145
Non-cash and operational adjustments Depreciation of property plant
& equipment
14,940
15,574
Amortization of intangible assets
7,628
4,975
Impairment of goodwill and intangible assets
-
177
Share-based payment expense
(140
)
(1,036
)
Loss (gain) on disposal of intangible assets and property, plant
& equipment
347
210
Movement in provisions
1,781
99
Movement reserve for bad debt and slow moving inventory
(23
)
255
Financial income
(7,405
)
(5,620
)
Financial expense
5,705
4,101
Impact of foreign currencies
(19
)
40
(Deferred) income taxes
960
591
Working capital adjustments
3,445
(5,890
)
Decrease (increase) in trade receivables and other receivables
(6,245
)
(10,920
)
Decrease (increase) in inventories and contracts in progress
(5,011
)
(1,423
)
Increase (decrease) in deferred revenue
10,252
2,898
Increase (decrease) in trade payables and other payables
4,449
3,555
Income tax paid & Interest received
(358
)
(776
)
Net cash flow from operating activities
24,709
25,845
for the twelve months endedDecember 31, In 000€
2022
2021
Investing activities Purchase of property, plant &
equipment
(21,608
)
(7,934
)
Purchase of intangible assets
(3,165
)
(3,788
)
Proceeds from the sale of property, plant & equipment &
intangible assets (net)
205
462
Acquisition of subsidiary (net of cash)
(29,355
)
(875
)
(Convertible) Loans granted
-
-
Investment in subsidiary, net of cash acquired
-
(999
)
Net cash flow used in investing activities
(53,923
)
(13,134
)
Financing activities Repayment of loans & borrowings
(20,044
)
(14,277
)
Repayment of leases
(3,379
)
(3,775
)
Capital increase
-
88,117
Interest paid
(1,990
)
(2,326
)
Other financial income (expense)
544
3,417
Net cash flow from (used in) financing activities
(24,869
)
71,156
Net increase/(decrease) of cash & cash equivalents
(54,082
)
83,867
Cash & Cash equivalents at the beginning of the year
196,028
111,538
Exchange rate differences on cash & cash equivalents
(1,078
)
624
Cash & cash equivalents at end of the period
140,867
196,028
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted
EBITDA (Unaudited)
for the three months endedDecember 31, for the twelve
months endedDecember 31, In 000€
2022
2021
2022
2021
Net profit (loss) for the period
(4,588
)
4,762
(2,153
)
13,145
Income taxes
(402
)
490
975
591
Financial expenses
4,216
919
4,420
4,101
Financial income
(780
)
(1,195
)
(6,114
)
(5,620
)
Depreciation and amortization
5,832
5,277
22,026
20,516
Share in loss of joint venture
-
-
-
-
EBITDA
4,278
10,253
19,154
32,733
Share-based compensation expense (1)
(20
)
44
(140
)
(833
)
Revaluation of fair value due to business combinations
-
8
-
-
Impairments (2)
-
177
-
177
Acquisition-related expenses of business combinations (3)
-
8
-
413
Adjusted EBITDA
4,258
10,490
19,014
32,490
(1) Share-based compensation expense represents the cost of
equity-settled and share-based payments to employees. (2)
Impairments represent the impairment of capitalized expenditures
related to the goodwill of metal company Aldema BV (177kEUR). (3)
Acquisition-related expenses of business combinations represent
expenses incurred in connection with the acquisition of our option
to buy Link3D.
Segment P&L (Unaudited)
In 000€
MaterialiseSoftware MaterialiseMedical
MaterialiseManufacturing Totalsegments Unallocated
(1) Consolidated For the three months ended December
31, 2022 Revenues
11,699
24,254
26,750
62,703
0
62,703
Segment (adj) EBITDA
(1,441
)
6,355
1,506
6,421
(2,163
)
4,258
Segment (adj) EBITDA %
-12.3
%
26.2
%
5.6
%
10.2
%
6.8
%
For the three months ended December 31, 2021 Revenues
12,183
20,682
24,124
56,989
(0
)
56,989
Segment (adj) EBITDA
5,518
6,358
990
12,866
(2,376
)
10,490
Segment (adj) EBITDA %
45.3
%
30.7
%
4.1
%
22.6
%
18.4
%
In 000€
MaterialiseSoftware MaterialiseMedical
MaterialiseManufacturing Totalsegments
Unallocated(1) Consolidated For the twelve months
ended December 31, 2022 Revenues
43,688
84,846
103,489
232,023
0
232,023
Segment (adj) EBITDA
1,514
18,822
8,229
28,565
(9,551
)
19,014
Segment (adj) EBITDA %
3.5
%
22.2
%
8.0
%
12.3
%
8.2
%
For the twelve months ended December 31, 2021 Revenues
42,902
73,368
89,180
205,450
0
205,450
Segment (adj) EBITDA
15,705
20,669
6,275
42,648
(10,158
)
32,490
Segment (adj) EBITDA %
36.6
%
28.2
%
7.0
%
20.8
%
15.8
%
(1) Unallocated segment adjusted EBITDA consists of corporate
research and development and corporate other operating income
(expense), and the added share-based compensation expenses,
acquisition related expenses of business combinations, impairments
and fair value of business combinations that are included in
Adjusted EBITDA.
Reconciliation of Net Profit (Loss) to Segment adjusted
EBITDA (Unaudited)
for the three months endedDecember 31, for the twelve
months endedDecember 31, In 000€
2022
2021
2022
2021
Net profit (loss) for the period
(4,588
)
4,762
(2,153
)
13,145
Income taxes
(402
)
490
975
591
Financial cost
4,216
919
4,420
4,101
Financial income
(780
)
(1,195
)
(6,114
)
(5,620
)
Share in loss of joint venture
-
-
-
-
Operating (loss) profit
(1,554
)
4,976
(2,872
)
12,217
Depreciation and amortization
5,832
5,277
22,026
20,516
Corporate research and development
594
812
2,600
2,948
Corporate headquarter costs
2,349
2,923
9,504
10,317
Other operating income (expense)
(800
)
(1,122
)
(2,693
)
(3,350
)
Segment adjusted EBITDA
6,421
12,866
28,565
42,648
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230214005059/en/
Investor Relations Harriet Fried LHA 212.838.3777
hfried@lhai.com
Materialise NV (NASDAQ:MTLS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Materialise NV (NASDAQ:MTLS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024